Orexin receptor antagonists
Psychiatry· 2 reviewed drugs· 2900 cited findings behind them
What the regulatory reviews cover
Orexin receptor antagonists reviewed in this library include DAYVIGO (lemborexant) and Quviviq (daridorexant). DAYVIGO is indicated for the treatment of insomnia in adults, characterized by difficulties with sleep onset and/or sleep maintenance. Quviviq is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least 3 months and considerable impact on daytime functioning.
Regulatory reviews for these drugs report various outcomes related to sleep. For DAYVIGO, the LSGM ratio of sSOL (Month 6 / Baseline) for lemborexant 10 mg vs placebo was 0.70. For Quviviq, the WASO change from baseline (LS mean difference vs placebo) was -22.78. It is important to note that different drugs were studied in different trials, and therefore, the reported figures are not head-to-head comparisons.
The drugs — one cited result each
| DAYVIGO Eisai Co., Ltd. | LSGM ratio of sSOL (Month 6 / Baseline) for lemborexant 10 mg vs placebo: 0.70 Eisai Co., Ltd. — Dayvigo FDA Review (NDA212028, ORIG 1, 201, p.149 |
| Quviviq Idorsia Ltd | WASO change from baseline (LS mean difference vs placebo): -22.78 Idorsia Ltd — Quviviq FDA Review, p.62 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Psychiatry research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.